The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The formulation is backed by over 80 clinical trials and 200 scientific publications
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Consolidated revenue from operations stood at Rs. 111.05 crore
Subscribe To Our Newsletter & Stay Updated